ライフサイエンスコーパス: cryptoxanthin

1 arotenoids, alpha-carotene, ss-carotene, and cryptoxanthin).

2 ein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin).

3 1)% after controlling for vitamin E and beta-cryptoxanthin.

4 .44 for beta-carotene, and r = 0.50 for beta-cryptoxanthin.

5 utein and 1.68 (95% CI: 0.99, 2.86) for beta-cryptoxanthin.

6 a-carotene, lutein, alpha-carotene, and beta-cryptoxanthin.

7 association was seen with vitamin E and beta-cryptoxanthin.

8 oids beta-carotene, alpha-carotene, and beta-cryptoxanthin.

9 5% CI: 0.84, 0.96; P-trend < 0.001) for beta-cryptoxanthin.

10 oxy xanthophylls lutein, zeaxanthin and beta-cryptoxanthin.

11 from 0.03 for beta-carotene to 0.40 for beta-cryptoxanthin.

12 nged from 0.13 for lycopene to 0.51 for beta-cryptoxanthin.

13 esponse and the colonic availability of beta-Cryptoxanthin.

14 sors alpha-carotene, beta-carotene, and beta-cryptoxanthin.

15 n C, alpha-carotene, beta-carotene, and beta-cryptoxanthin.

16 ha-carotene, 0.35; beta-carotene, 0.28; beta-cryptoxanthin, 0.35; lutein/zeaxanthin, 0.28; lycopene,

17 carotene, 0.95 (95% CI: 0.70, 1.29) for beta-cryptoxanthin, 0.82 (95% CI: 0.60, 1.12) for lycopene, 0

18 .5, and 54.6 micro mol/L, respectively; beta-cryptoxanthin: 0.12, 0.16, and 0.16 micro mol/L, respect

19 ycopene (28%), lutein/zeaxanthin (17%), beta-cryptoxanthin (15%), total carotenoids (16%), serum beta

20 (5-fold), alpha-carotene (19-fold), and beta-cryptoxanthin (2-fold) concentrations; total-body vitami

21 ene (1483%), alpha-carotene (145%), and beta-cryptoxanthin (67%) (P < or = 0.0001).

22 The concentrations of plasma lutein, cryptoxanthin, alpha-carotene, 13-cis-beta-carotene, all

23 otective factor(s) against lung cancer; that cryptoxanthin, alpha-carotene, and ascorbic acid need to

24 Serum levels of lycopene, lutein, cryptoxanthin, alpha-carotene, and beta-carotene were as

25 scores for other carotenoids, including beta-cryptoxanthin, alpha-carotene, and beta-carotene, were a

26 lasma and BMC concentrations of lutein, beta-cryptoxanthin, alpha-carotene, and beta-carotene.

27 k, whereas no association was found for beta-cryptoxanthin, alpha-carotene, and beta-carotene.

28 toene, phytofluene, lutein, zeaxanthin, beta-cryptoxanthin, alpha-carotene, beta-carotene and lycopen

29 association between serum carotenoids (beta-cryptoxanthin, alpha-carotene, beta-carotene, lutein/zea

30 difference in beta-carotene relative to beta-cryptoxanthin and 36% of the variation and 4-fold differ

31 lasma and lipoprotein concentrations of beta-cryptoxanthin and alpha- and beta-carotene than did men.

32 Levels of lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in hexane extracts were

33 were generated for lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in kaki, peach and apric

34 ibutors to TEAC activity, while lutein, beta-cryptoxanthin and beta-carotene were primary contributor

35 minor carotenoids were antheraxanthin, beta-cryptoxanthin and beta-carotene, while zeaxanthin was ab

36 evels were 15-fold higher than those of beta-cryptoxanthin and beta-carotene.

37 Recent epidemiological data on beta-cryptoxanthin and cardiovascular disease are lacking.

38 thophylls such as lutein, zeaxanthin or beta-cryptoxanthin and carotenes such as beta-carotene, which

39 among women reporting intake values of beta-cryptoxanthin and lutein/zeaxanthin in the upper 2 quart

40 il) on the in vitro bioaccessibility of beta-Cryptoxanthin and phytosterols, a MFGM containing bevera

41 ween higher intake of beta-carotene and beta-cryptoxanthin and risk of hearing loss.

42 ntioxidants were modeled together, only beta-cryptoxanthin and supplemental zinc were statistically s

43 ntioxidant micronutrients, particularly beta-cryptoxanthin and supplemental zinc, and possibly diets

44 tene, lycopene, lutein, zeaxanthin, and beta-cryptoxanthin and the risk of colon cancer.

45 nts of mono-esterified lauric acid with beta-cryptoxanthin and with cryptocapsin.

46 itamin A carotenoids (beta-carotene and beta-cryptoxanthin) and capsanthin were present at highest co

47 concentrations (lutein + zeaxanthin and beta-cryptoxanthin) and hydrocarbon carotenoids (lycopene, al

48 , lutein plus zeaxanthin, lycopene, and beta-cryptoxanthin) and risk of HNC and HNC subtypes in a lar

49 carotene, 0.91 (95% CI: 0.46, 1.81) for beta-cryptoxanthin, and 1.35 (95% CI: 0.68, 2.69) for lutein/

50 wk apart were > or = 0.89 for lycopene, beta-cryptoxanthin, and alpha- and beta-carotene.

51 sayed for ascorbic acid, beta-carotene, beta-cryptoxanthin, and alpha- and gamma-tocopherol.

52 alpha-carotene, beta-carotene, lutein, beta-cryptoxanthin, and ascorbic acid increased by more in th

53 e oxidative cleavage of alpha-carotene, beta-cryptoxanthin, and beta-apo-8'-carotenal to yield retina

54 Furthermore, the BA of lutein, beta-cryptoxanthin, and beta-cryptoxanthin esters was shown t

55 Higher intakes of beta-carotene, beta-cryptoxanthin, and folate, whether total or from diet, a

56 ricans had higher mean serum vitamin C, beta-cryptoxanthin, and lutein + zeaxanthin but lower folate

57 tions of alpha-carotene, beta-carotene, beta-cryptoxanthin, and lutein+zeaxanthin were 0.25, 0.29, 0.

58 nd intakes of vitamin C, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food (P < 0.05

59 kes of vitamins C and E, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food, or a die

60 kes of vitamins C and E, beta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food: 0.27 (0.

61 ycopene, alpha-carotene, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin were similar in cas

62 ctors of beta-carotene, alpha-carotene, beta-cryptoxanthin, and lutein/zeaxanthin.

63 ha-carotene, beta-carotene, zeaxanthin, beta-cryptoxanthin, and lycopene.

64 e retina accumulated zeaxanthin, lutein, and cryptoxanthin, and preferentially absorbed zeaxanthin (P

65 Lycopene, beta-cryptoxanthin, and vitamin C were not associated with re

66 alpha-carotene, beta-carotene, lutein, beta-cryptoxanthin, and zeaxanthin, showed no association wit

67 spiratory health and that vitamin E and beta-cryptoxanthin appear to be stronger correlates of lung f

68 ith the exception of this activity with beta-cryptoxanthin, BCO2 cleaves specifically at the 9'-10' b

69 ficantly lower among cases than controls for cryptoxanthin, beta-carotene, and lutein/zeaxanthin with

70 In general, beta-cryptoxanthin (betaCX) had higher retention than beta-ca

71 rgistic relationships were observed for beta-cryptoxanthin concentration after irradiation.

72 t to between-subject variance ratio for beta-cryptoxanthin concentration was higher (0.23; 95% CI: 0.

73 ficantly lower plasma ascorbic acid and beta-cryptoxanthin concentrations than did nonsmokers and pas

74 carotenoid, alpha-carotene, ss-carotene, and cryptoxanthin concentrations than did those who lived in

75 r 0 sum of provitamin A carotenoids and beta-cryptoxanthin concentrations were associated with maximu

76 There was a trend toward lower adjusted beta-cryptoxanthin concentrations with increasing level of fi

77 rotenoids, alpha- and beta-carotene and beta-cryptoxanthin, constituted 51% of median total carotenoi

78 The potential of beta-cryptoxanthin (CX)-rich foods to form vitamin A (VA) in

79 a-Cryptoxanthin, tentatively identified beta-Cryptoxanthin esters and the ratio cis-/trans-beta-carot

80 e BA of lutein, beta-cryptoxanthin, and beta-cryptoxanthin esters was shown to be superior to that of

81 In all acidic media, beta-cryptoxanthin exhibited the lowest degradation rates fol

82 o tailor asymmetric carotenoids such as beta-cryptoxanthin for vitamin A production.

83 otene, lycopene, lutein/zeaxanthin, and beta-cryptoxanthin, have been examined in a number of epidemi

84 evels that were 27% (lycopene) to 178% (beta-cryptoxanthin) higher than those of subjects in the lowe

85 e, beta-carotene, lutein, lycopene, and beta-cryptoxanthin in 2 large cohorts.

86 arly beta-carotene, alpha-carotene, and beta-cryptoxanthin, in both the supplemented and unsupplement

87 and serum concentrations of lutein and beta-cryptoxanthin increased across the groups in a dose-depe

88 ciation with beta-carotene, lutein, and beta-cryptoxanthin intakes were inverse but not significant.

89 tenoid peaks (alpha- and beta-carotene, beta-cryptoxanthin, lutein, and lycopene) plus alpha- and gam

90 carotenoids (alpha- and beta-carotene, beta-cryptoxanthin, lutein, and lycopene), retinol, and alpha

91 the lowest serum vitamin B-12, folate, beta-cryptoxanthin, lutein, and zeaxanthin concentrations.

92 s fraction of alpha- and beta-carotene, beta-cryptoxanthin, lutein, lycopene and zeaxanthin in minima

93 arotene, beta-carotene, total carotene, beta-cryptoxanthin, lutein, lycopene, retinol, and ascorbic a

94 entrations of alpha-carotene, beta-carotene, cryptoxanthin, lutein/zeaxanthin, and lycopene in 40- to

95 levels of antioxidants alpha-carotene, beta-cryptoxanthin, lutein/zeaxanthin, and lycopene were sign

96 tenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, and lycopene) in a ran

97 mins C and E, retinol, and carotenoids (beta-cryptoxanthin, lutein/zeaxanthin, beta-carotene, and lyc

98 t associations of vitamin C, vitamin E, beta-cryptoxanthin, lutein/zeaxanthin, beta-carotene, and ret

99 either project for alpha- and beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, alpha-tocoph

100 takes of alpha-carotene, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, folate, and

101 94, the carotenoids lutein, zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, and beta-carote

102 Lutein, beta-cryptoxanthin, lycopene, alpha-carotene, retinol, and al

103 takes of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene, and lutein + zeaxanthin and bre

104 tenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein) and TB incidence wa

105 intake (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein+zeaxanthin) with BMD

106 ncluding alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein-zeaxanthin, blood li

107 h levels of circulating alpha-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were asso

108 evels of alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were meas

109 tenoids (alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin) to level

110 nd E and alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin from foo

111 carotenoids (alpha- and beta-carotene, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin) were me

112 n plasma alpha-carotene, beta-carotene, beta-cryptoxanthin, lycopene, lutein/zeaxanthin, retinol, alp

113 pherols), and carotenoid (lutein/zeaxanthin, cryptoxanthins, lycopene, and alpha- and beta-carotene)

114 Except for alpha-carotene and cryptoxanthin, none of the model carotenoids or retinol

115 ix weeks provoked an increment in serum beta-Cryptoxanthin of 38.9mug/dl (CI 95%; 31.0, 46.8; p<0.001

116 .54 [0.38-0.78]; P(trend) = .003), and alpha-cryptoxanthin (OR = 0.53 [0.36-0.78]; P(trend) = .003) w

117 carotene (OR, 0.91; 95% CI, 0.86-0.96), beta cryptoxanthin (OR, 0.91; 95% CI, 0.84-0.99), lutein/zeax

118 CI: 0.1, 1.2; P = 0.13 for linear trend) and cryptoxanthin (OR: 0.3; 95% CI: 0.1, 1.3; P = 0.11 for l

119 -carotene, beta-carotene, lycopene, and beta-cryptoxanthin) or vitamin A after other potential risk f

120 0.002), beta-carotene (P < 0.001), and beta-cryptoxanthin (P < 0.001) concentrations.

121 < 0.001), 9.1 and 8.0 microg/liter for beta-cryptoxanthin (p < 0.001), and 50.6 and 46.8 microg/lite

122 had higher alpha-carotene (P < 0.001), beta-cryptoxanthin (P < 0.001), and lutein and zeaxanthin (P

123 nd adolescents had significantly higher beta-cryptoxanthin (P < 0.001), lutein and zeaxanthin (P < 0.

124 d carotenoid esters, beta-carotene, and beta-cryptoxanthin palmitate were the most abundant in peels

125 e (r = 0.40), beta-carotene (r = 0.28), beta-cryptoxanthin (r = 0.41), lutein (r = 0.23), and vitamin

126 were also consistently detected in BCO2-beta-cryptoxanthin reaction mixtures.

127 Auroxanthin and beta-cryptoxanthin represented around 50% of total carotenoid

128 ein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin, respectively.

129 carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin), retinol, and tocopherols (alpha-tocopher

130 carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin, retinol, alpha-tocopherol, gamma-tocopher

131 e there was an inverse association with beta-cryptoxanthin (RR = 0.59, 95% CI: 0.39, 0.90; p-trend =

132 In faeces, free beta-Cryptoxanthin, tentatively identified beta-Cryptoxanthin

133 genated carotenoids (lutein, zeaxanthin, and cryptoxanthin), three hydro-carbon carotenoids (alpha-ca

134 tegories of intake ranged from 0.80 for beta-cryptoxanthin to 0.89 for alpha-carotene and lutein-zeax

135 s-zeaxanthin, total trans-lutein/zeaxanthin, cryptoxanthin (total and beta), total trans-lycopene and

136 carotene, lycopene, lutein/zeaxanthin, alpha-cryptoxanthin, total carotenoids, retinol, alpha-tocophe

137 -carotene, beta-carotene, lycopene, and beta-cryptoxanthin), vitamin A, and retinol were not associat

138 -carotene, lutein/zeaxanthin, lycopene, beta-cryptoxanthin, vitamin A, serum beta-carotene, and serum

139 A decrease of beta-cryptoxanthin was observed at higher temperatures, where

140 tamin A carotenoids, beta-carotene, and beta-cryptoxanthin were each inversely associated with a decl

141 tandard deviation of serum vitamin E or beta-cryptoxanthin were equivalent to the negative influence

142 As for FEV(1)%, vitamin E and beta-cryptoxanthin were most strongly related to FVC% when al

143 ietary intakes of lutein+zeaxanthin and beta-cryptoxanthin were not associated with breast cancers de

144 hough the pooled RRs for quintile 5 for beta-cryptoxanthin were not significant, inverse trends were

145 ed carotenoids (lutein, zeaxanthin, and beta-cryptoxanthin) were detected at electrical potential set

146 cis isomers, cis anhydrolutein, and cis beta-cryptoxanthin) were inversely associated with 15-F(2t)-I

147 xanthophylls (cis-violaxanthin, lutein, beta-cryptoxanthin, zeaxanthin and cis-antheraxanthin) were i